ClinicalTrials.gg
RecruitingNCT06836219BeLIVEUpdated Feb 20, 2025

Measure of Outcomes in Patients With Advanced Ovarian Cancer According to Homologous Recombination Status and Matched Therapies in a Real-world Scenario

An observational study in Ovarian Cancer, sponsored by Consorzio Oncotech. Recruiting at 21 sites in Italy. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-20.

Sponsored by Consorzio Oncotech · Observational

How we know · 2 judgments

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
300
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 267 studies in Ovarian Neoplasms with a site in Italy — 82 open to participants now, 116 under way, 29 of them phase 3. Ovarian Neoplasms · Italy.

Planned enrollment
20th of 57
300 · median 200
Started
2024
with 24 others
Observational
57 of 267
33 open now
Primary completion
2029-01
later than 96 of 115 live
Registered
232nd of 267
by date

Among the 267 studies in Ovarian Neoplasms with a site in Italy, this one is the 20th largest by planned enrollment of the 57 observational ones that give a count, is one of 25 that started in 2024, is one of 57 observational ones, reaches primary completion later than 96 of the 115 other live ones, and was the 232nd registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

82 of the 267 studies in Ovarian Neoplasms with a site in Italy are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 267 studies in Ovarian Neoplasms with a site in Italy, or all of them as a file.
02

Study summary

This is a retrospective and prospective, multicenter, observational, two-cohorts study aimed to evaluate clinical outcomes and safety of patients diagnosed with advanced high grade ovarian cancer whose tumor was tested for the homologous recombination (HR) status using a validated HR deficiency test between January 2021 and January 2026.

  • Cohort A: Homologous Recombination Deficient (HRD) ovarian cancer patients treated with Olaparib plus Bevacizumab as maintenance therapies after partial or complete response to first line platinum-based chemotherapy.
  • Cohort B: Homologous Recombination Proficient (HRP) ovarian cancer patients treated as for standard clinical practice at clinician's choice.
Read the detailed description

This is a retrospective and prospective, multicenter, observational, two-cohorts study aimed to evaluate clinical outcomes and safety of patients diagnosed with advanced high grade ovarian cancer whose tumor was tested for the homologous recombination status using a validated HRD test between January 2021 and January 2026:

Cohort A: Homologous Recombination Deficient (HRD) ovarian cancer patients treated with Olaparib plus Bevacizumab as maintenance therapies after partial or complete response to first line platinum-based chemotherapy.

Cohort B: Homologous Recombination Proficient (HRP) ovarian cancer patients treated as for standard clinical practice at clinician's choice. Alive patients who have finished the first line treatment (including maintenance) with or without disease progression while signing the informed consent form will be enrolled retrospectively. Alive patients candidate to receive a first line therapy will be enrolledprospectively as soon as molecular data (BRCA status and HRD) are available.

03

Conditions studied

  • Ovarian Cancer

Browse trials for

Keywords

  • Ovarian Cancer
  • Homologous Recombination status
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients diagnosed with advanced high grade ovarian cancer who have received a homologous recombination analysis using validated HRD test between January 2021 and January 2026 are eligible. Patients resulted HRD and treated with Olaparib plus Bevacizumab will be included in Cohort A while patient with HRP tumors will be included in the Cohort B. Patients enrolled in the "compassionate use" of Olaparib (CNN program) can be included as well as patients who have received therapies according to clinical practice.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female, age ≥ 18 years at the time of diagnosis
  • Patients diagnosed with high-grade serous or endometroid ovarian, fallopian tube, or primary peritoneal cancer undergone to Homologous Recombination test with the MyChoice HRD assay, FoundationOne DX assay or another validated HRD test, between January 2021 and January 2026:

    • Patients with HRD score > 42 or Loss of Heterozygosity (LOH) score high or defined as HR deficient with other tests and treated with Bevacizumab and Olaparib after platinumbased chemotherapy will be retrospectively or prospectively enrolled in Cohort A
    • Patients with HRD score \< 42 or Loss of Heterozygosity (LOH) score low or defined as HR proficient with other tests and treated with first line platinum-based chemotherapy with or without bevacizumab or others targeted agents will be retrospectively or prospectively enrolled in Cohort B
  • Patients must be able to understand the study procedures and agree to participate in the study by providing written .

Exclusion criteria

Exclusion Criteria:

  • Patients who have not performed a validated Homologous Recombination test on tumor sample.
  • Patients with germline or somatic BRCA 1 or 2 mutations
  • Patients death at the time of inclusion in the current study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort A: Homologous Recombination Deficient (HRD)

    Homologous Recombination Deficient (HRD) ovarian cancer patients treated with Olaparib plus Bevacizumab as maintenance therapies after partial or complete response to first line platinum-based chemotherapy.

  • Cohort B: Homologous Recombination Proficient (HRP)

    Homologous Recombination Proficient (HRP) ovarian cancer patients treated as for standard clinical practice at clinician's choice.

This study also gives OlaparibStudies of OlaparibOlaparib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Evaluate the clinical outcomes

    The clinical outcomes that will be measured in both study cohorts are: progression-free survival (PSF) as the time from treatment's start to disease progression or death for any cause

    Time frame: Until 3 years from enrollment

  2. Evaluate the clinical outcomes

    The clinical outcomes that will be measured in both study cohorts are: overall survival (OS) as the time from treatment's start to death for any cause

    Time frame: Until 3 years from enrollment

  3. Evaluate the safety in patients treated with targeted anticancer therapies in each study cohort

    Toxicity evaluated according to CTCAE vers 5.0

    Time frame: Until 3 years from enrollment

  4. Evaluate the safety in patients treated with targeted anticancer therapies in each study cohort

    Percentage of patients with dose reductions

    Time frame: Until 3 years from enrollment

  5. Evaluate the safety in patients treated with targeted anticancer therapies in each study cohort

    Percentage of patients with dose interruptions due to toxicity

    Time frame: Until 3 years from enrollment

  6. Evaluate the safety in patients treated with targeted anticancer therapies in each study cohort

    Percentage of patients with treatment discontinuations due to toxicity

    Time frame: Until 3 years from enrollment

  7. Evaluate the safety in patients treated with targeted anticancer therapies in each study cohort

    Toxicity according to initial dose of targeted agents

    Time frame: Until 3 years from enrollment

  8. Evaluate the safety in patients treated with targeted anticancer therapies in each study cohort

    Incidence of myelodysplastic syndrome and acute myeloid leukaemia in patients receiving PARPi

    Time frame: Until 3 years from enrollment

Secondary outcomes

  1. Describe the clinical outcomes

    according to disease stage

    Time frame: Until 3 years from enrollment

  2. Describe the clinical outcomes

    according to surgical timing

    Time frame: Until 3 years from enrollment

  3. Describe the clinical outcomes

    according to residual disease after surgery in each cohort

    Time frame: Until 3 years from enrollment

  4. Describe the clinical characteristics of patients for which the combination therapy was offered (Cohort A)

    Describe the clinical characteristics of patients for which the combination therapy was offered (Cohort A)

    Time frame: Until 3 years from enrollment

  5. Describe the treatment approach to HRP patients in a real word scenario in Italy (Cohort B)

    Describe the treatment approach to HRP patients in a real word scenario in Italy (Cohort B)

    Time frame: Until 3 years from enrollment

07

Study locations

20 of 21 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Jan 2029, 52 months after the start.

Of 216 non-industry observational studies under Ovarian Neoplasms, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 206. This study's planned 52 months is below that.

Counting every sponsor, half of 268 studies reached it within 61 months; a quarter within 35 and three quarters within 185.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2025
First posted
Feb 20, 2025
StartActual
Sep 13, 2024
Primary completionEst.
Jan 2029
CompletionEst.
Jan 2029
Last update
Feb 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06836219
Lead sponsor
Consorzio Oncotech
Responsible party
Sponsor
First posted
Feb 20, 2025
Start date
Sep 13, 2024
Primary completion
Jan 2029 (estimated)
Completion
Jan 2029 (estimated)
Last update
Feb 20, 2025

Study contacts

Michele B Michele Bartoletti, MD
Contact
michele.bartoletti@cro.it
+39 334 500 7736 ext. 334 500 7736
BeLIVE S BeLIVE Service
Contact
belive@cr-technology.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion